LTR Pharma

LTR Pharma has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc., a leading U.S. Section 503A compounding pharmacy, converting the previously announced binding Term Sheet into a definitive commercial agreement governing the planned manufacturing, compounding, fulfilment and nationwide supply of ROXUS® in the United States.  The agreement establishes the operational framework for

LTR Pharma has executed a definitive Telehealth Distribution Agreement with Shed Holdings LLC, a leading U.S. direct-to-consumer telehealth platform, converting the previously announced binding Term Sheet into a definitive commercial agreement governing the planned U.S. commercialisation of ROXUS®. The agreement establishes the commercial framework for the planned U.S. commercialisation of ROXUS. Shed will commercialise

LTR Pharma has signed a term sheet with Strive Specialties, a United States personalised medicine and 503A pharmacy for ROXUS®.   This establishes the pharmacy fulfilment infrastructure required to supply ROXUS in the US and follows our announcement earlier this week that Shed Holdings, a direct-to-consumer (DTC) telehealth platform, will be a US distributor for